• 1
    Audibert F.M., Lise D. (1993) Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 14: 2814.
  • 2
    Mark A., Bjorksten B., Granstrom M. (1995) Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines. Vaccine 13: 66973.
  • 3
    Gregoriadis G. (1990) Immunological adjuvants: a role for liposomes. Immunol Today 11: 8997.
  • 4
    Alving C.R., Koulchin V., Glenn G.M., Rao M. (1995) Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol Rev 145: 531.
  • 5
    De Haan A., Tomee J.F.C., Huchshorn J.P., Wilschut J. (1995) Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. Vaccine 13: 13204.
  • 6
    Gluck R. (1995) Liposomal presentation of antigens for human vaccines. Pharm Biotechnol 6: 32545.
  • 7
    Gregoriadis G. (1994) Liposomal presentation of antigens for human vaccines. Immunomethods 4: 2106.
  • 8
    Shahum E., Therien H.M. (1988) Immunopotentiation of the humoral response by liposomes: encapsulation versus covalent linkage. Immunology 65: 3157.
  • 9
    Fortin A., Shaum E., Krzystyniak K., Therien H.M. (1996) Differential activation of cell-mediated immune functions by encapsulated and surface-linked liposomal antigens. Cell Immunol 169: 20817.
  • 10
    Naito S., Horino A., Nakayama M., Nakano Y., Nagai T., Mizuguchi J., Komuro K., Uchida T. (1996) Differential activation of cell-mediated immune functions by encapsulated and surface-linked liposomal antigens. Int Arch Allergy Immunol 109: 2238.
  • 11
    Nakano Y., Mori M., Nishinohara S., Takita Y., Naito S., Horino A., Kato H., Taneichi M., Komuro K., Uchida T. (1999) Antigen-specific, IgE-selective unresponsiveness induced by antigen-liposome conjugates. Comparison of four different conjugation methods for the coupling of antigen to liposome. Int Arch Allergy Immunol 120: 199208.
  • 12
    Nakano Y., Mori M., Nishinohara S., Takita Y., Naito S., Kato H., Taneichi M., Komuro K., Uchida T. (2001) Surface-linked liposomal antigen induces IgE-selective unresponsiveness regardless of the lipid components of liposomes. Bioconjugate Chemistry 12: 3915.
  • 13
    Taneichi M., Naito S., Kato H., Tanaka Y., Mori M., Nakano Y., Yamamura H., Ishida H., Komuro K., Uchida T. (2002) T cell-independent regulation of IgE antibody production induced by surface-linked liposomal antigen. J Immunol 169: 424652.
  • 14
    Uchida T. (2003) Surface-linked liposomal antigen induces IgE selective unresponsiveness in a T-cell independent fashion. Curr Drug Targets Immune Endocr Metabol Disord. 3: 11935.
  • 15
    Uchida T. (2003) STX-liposome conjugates as candidate vaccines. Drugs of Today 39: 67393.
  • 16
    Taneichi M., Ishida H., Kajino K., Ogasawara K., Tanaka Y., Kasai M., Mori M., Nishida M., Yamamura H., Mizuguchi J., Uchida T. (2006) Antigens chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity. J Immunol 177: 23230.
  • 17
    CDC, Morbidity and Mortality Weekly Report, serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR 58 (2009) 5214.
  • 18
    Gatherer D. (2009) The 2009 H1N1 influenza outbreak in its historical context. J Clin virol 45: 1748.
  • 19
    Olsen B., Munster V.J., Wallensten A., Waldenström J., Osterhaus A.D., Fouchier R.A. (2006) Global patterns of influenza A virus in wild birds. Science 312: 3848.
  • 20
    Effros R.B., Doherty P.C., Gerhard W., Bennink J. (1977) Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J Exp Med 145: 55768.
  • 21
    Kreijtz J.H., de Mutsert G., van Baalen C.A., Fouchier R.A., Osterhaus A.D., Rimmelzwaan G.F. (2008) Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82: 51616.
  • 22
    Lee L.Y., Hado L.A., Simmons C., de Jong M.D., Chau N.V., Schumacher R., Peng Y.C., McMichael A.J., Farrar J.J., Smith G.L., Townsend A.R., Askonas B.A., Rowland-Jones S., Dong T. (2008) Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118: 347890.
  • 23
    Heath W.R., Carbone F.R. (2001) Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19: 4764.
  • 24
    Glenny A.T., Pope C.G. (1926) Immunology notes. XXIII. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 29: 3140.
  • 25
    Aggrebeck H., Wantzin J., Heon I. (1996) Booster vaccination against diphtheria and tetanus in man: comparison of three different vaccine formations-III. Vaccine 14: 126572.
  • 26
    Uchida T., Taneichi M. (2008) Clinical application of surface-linked liposomal antigens. Mini-Rev Med Chem 8: 18492.
  • 27
    Nagata T., Toyota T., Ishigaki H., Ichihashi T., Kajino K., Kashima Y., Itoh Y., Mori M., Oda H., Yamamura H., Taneichi M., Uchida T., Ogasawara K. (2007) Peptides coupled to the surface of a kind of liposome protect infection of influenza viruses. Vaccine 25: 491421.
  • 28
    Tanaka Y., Kasai M., Taneichi M., Naito S., Kato H., Mori M., Nishida M., Maekawa N., Yamamura H., Komuro K., Uchida T. (2004) Liposomes with differential lipid components exert differential adjuvanticity in antigen−liposome conjugates via differential recognition by macrophages. Bioconjugate Chem 15: 3540.
  • 29
    Rock K.L. (1996) A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 17: 1317.
  • 30
    Carbone F.R., Bevan M.J. (1990) Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 171: 37787.
  • 31
    Liu T., Zhou X., Orvell C., Leferer E., Ljunggren H.G., Jondal M. (2002) Heat-inactivated Sendai virus can enter multiple MHC class I processing pathways and generate cytotoxic T lymphocyte responses in vivo. J Immunol 154: 314755.
  • 32
    Zinkernagel R.M. (2002) On cross-priming of MHC class I-specific CTL: rule or exception? Eur J Immunol 32: 238592.
  • 33
    Houde M., Berholet S., Gagnon E., Brunet S., Goyette G., Laplante A., Princlotta M.F., Thibault P., Sacks D., Desjardins M. (2003) Phagosomes are competent organelles for antigen cross-presentation. Nature 425: 4026.
  • 34
    Ackerman A.L., Cresswell P. (2004) Cellular mechanisms governing cross-presentation of exogenous antigens. Nature Immunol 15: 67884.
  • 35
    Blattman J.N., Greenberg P.D. (2004) Cancer immunotherapy: a treatment for the masses. Science 305: 2005.
  • 36
    Dermime S., Gilham D.E., Shaw D.M., Davidson E.J., Meziane el-K., Armstrong A., Hawkins R.E., Stern P.L. (2004) Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta 1704: 1135.
  • 37
    Vicari A.P., Chiodoni C., Vaure C., Ait-Yahia S., Dercamp C., Matsos F., Reynard O., Taverne C., Merle P., Colombo M.P., O’Garra A., Trinchieri G., Caux C. (2002) Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 196: 5419.
  • 38
    Phillips N.C., Gagne L., Ivanoff N., Riveau G. (1996) Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens. Vaccine 14: 898904.
  • 39
    Suzaki Y., Ami Y., Nagata N., Naito S., Kato H., Taneichi M., Takahashi M., Komiya T., Satoh S., Gondaira F., Sugiyama J., Nakano Y., Mori M., Komuro K., Uchida T. (2002) Protection of monkeys against Shiga toxin induced by Shiga toxin-liposome conjugates. Int Arch Allergy Immunol 127: 2948.
  • 40
    Garcon N., Gregoriadis G., Taylor M., Summerfield J. (1988) Mannose-mediated targeted immunoadjuvant action of liposomes. Immunology 64: 7435.
  • 41
    Matsui M., Kohyama S., Suda T., Yokoyama S., Mori M., Kobayashi A., Taneichi M., Uchida T. (2010) A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice. Biochem Biophys Res Commun 391: 14949.
  • 42
    Gotch F., Rothbard J., Howland K., Townsend A., McMichael A. (1987) Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 326: 8812.
  • 43
    Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., Nabel G.J. (2005) Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 540410.
  • 44
    Townsend A.R., Rothbard J., Gotch F.M., Bahadur G., Wraith D., McMichael A.J. (1986) The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44: 44,95968.
  • 45
    Berkhoff E.G., de Wit E., Geelhoed-Mieras M.M., Boon A.C., Symons J., Fouchier R.A., Osterhaus A.D., Rimmelzwaan G.F. (2005) Functional constrains of influenza A virus epitopes limit escape from cytotoxic T lymphocytes. J Virol 79: 11,23946.
  • 46
    Doherty P.C., Kelso A. (2008) Toward a broadly protective influenza vaccine. J Clin Invest 118: 32735.
  • 47
    Thomas P.G., Keating R., Hulse-Post D.J., Doherty P.C. (2006) Cell-mediated protection in influenza infection. Emerg Infect Dis 12: 4854.